NCT05768867

Completed

French Translation and Validation of the PEYronie's Disease ...

University Hospital, Toulouse Source

Compare

Other study identifiers

Sponsor study identifier

RC31/23/0012

Secondary identifiers

2023-A00219-36

REGISTRY · ANSM

Study Type

observational

Actual enrollment (reported)

30

Locations

1 country

Sites

1

Timeline

Study Start

March 6, 2023

Actual (reported)

Primary Completion

May 22, 2023

Actual (reported)

Study Completion

May 22, 2023

Actual (reported)

Brief Summary

This study is a prospective cohort dedicated to peyronie's disease. The aim is to validate the french translation of the peyronie's disease questionnaire. The primary endpoint is the response rate to the questionnaire.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 30 participants
Study completion date: May 22, 2023
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
March 3, 2023
Actual (reported)
Study Start
March 6, 2023
Actual (reported)
First Posted
March 14, 2023
Actual (reported)
Primary Completion
May 22, 2023
Actual (reported)
Study Completion
May 22, 2023
Actual (reported)

Last Updated: August 27, 2024
Status Verified: August 2024
Last Update Submitted: August 26, 2024

Conditions

Peyronie Disease

Outcome Measures

Primary Outcomes (1)

Rate of responses
Response rate to the online questionnaire.
Day 0

Interventions

FRAnçaise du PEYronie's Disease QUESTionnaireOther

Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with Peyronie's Disease

You may qualify if:

Adult patient with Peyronie's Disease clinically diagnosed during a consultation, with palpation of at least one plaque

You may not qualify if:

Sponsors & Collaborators

University Hospital, Toulouse
Otherlead

Study Sites (1)

Toulouse Hospital

Toulouse, France

MeSH Terms

Conditions

Penile Induration

Condition Hierarchy (Ancestors)

Penile DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

Eric Huyghe, MD
University Hospital, Toulouse
PRINCIPAL INVESTIGATOR

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 3, 2023

First Posted

March 14, 2023

Study Start

March 6, 2023

Actual (reported)

NCT06303661

Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease

Not ApplicableUnknown

NCT05871177

Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

Not ApplicableCompleted

NCT04370652

Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum

Completed

NCT06621420

Peyronie Disease Questionnaire (PDQ): Turkish Validation

Unknown

NCT06649539

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Phase 4Active Not Recruiting

NCT05316714

Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment

Not ApplicableUnknown

Patient refusing to participate
Patient with difficulties in understanding the French language.
Protected persons referred to in articles L.1121-6 to L.1121-8 of the public health code

Contact the study team to confirm eligibility.

Primary Completion

May 22, 2023

Actual (reported)

Study Completion

May 22, 2023

Actual (reported)

Last Updated

August 27, 2024

Record last verified: 2024-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05768867
Data provider: ClinicalTrials.gov
Source updated: 2024-08-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:20:55 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations